222 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
TSRO TESARO, Inc. $35.07 $1.93B Uptrend
Article Searches
Cancer Investing Highlight: Clovis Scores A Breakthrough, Now For The Breakout? https://seekingalpha.com/article/4209502-cancer-investing-highlight-clovis-scores-breakthrough-now-breakout?source=feed_sector_healthcare Oct 03, 2018 - Clovis Oncology has struggled to set itself apart from other PARP inhibitor developers over the past few years.A new breakthrough therapy designation could signal a move into an alternate disease land
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC http://www.zacks.com/stock/news/326077/clovis-rubraca-gets-breakthrough-therapy-status-for-mcrpc?cid=CS-ZC-FT-326077 Oct 03, 2018 - Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
Here's Why J&J (JNJ) is a Good Bet in a Troubled Market http://www.zacks.com/stock/news/326064/heres-why-jj-jnj-is-a-good-bet-in-a-troubled-market?cid=CS-ZC-FT-326064 Oct 03, 2018 - A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.
How Tesaro Hopes to Tackle Lung Cancer https://www.fool.com/investing/2018/09/07/how-tesaro-hopes-to-tackle-lung-cancer.aspx?source=iedfolrf0000001 Sep 07, 2018 - The company is advancing a research program that it hopes will improve outcomes for patients with non-small cell lung cancer.
Constellation Pharmaceuticals Readies $80 Million IPO Plans https://seekingalpha.com/article/4186954-constellation-pharmaceuticals-readies-80-million-ipo-plans?source=feed_tag_ipo_analysis Jul 12, 2018 - Constellation Pharmaceuticals intends to sell $80 million of its common stock in a U.S. IPO.The firm is developing treatment candidates for a variety of cancers and myelofibrosis diseases.CNST has sho
Evaluation Of Tesaro: Fair Value And Acquisition Potential https://seekingalpha.com/article/4186853-evaluation-tesaro-fair-value-acquisition-potential?source=feed_sector_healthcare Jul 12, 2018 - Understanding the root cause for the falling stock price in the last 1.5 years.Improved upside for future revenue growth with more indications.Strong pipeline on Immunotherapy assets.Slightly underval
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing http://www.zacks.com/stock/news/310515/clovis-gets-eu-acceptance-for-rubraca-label-expansion-filing?cid=CS-ZC-FT-310515 Jul 06, 2018 - Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C. https://seekingalpha.com/article/4178985-stocks-watch-eyes-apples-wwdc-scotus-d-c?source=feed_tag_editors_picks Jun 02, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Tesaro: Can Upcoming Catalyst Bring Fortune To This Unpopular Company? https://seekingalpha.com/article/4178742-tesaro-can-upcoming-catalyst-bring-fortune-unpopular-company?source=feed_sector_healthcare Jun 01, 2018 - Tesaro traded into the deep south for the past 52 weeks. Nevertheless, the fundamentals are improving, thus signaling a trading reversal in the making.Revenues from the approved product, niraparib (Ze
Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer http://www.zacks.com/stock/news/305627/clovis-rubraca-gets-approval-in-europe-for-ovarian-cancer?cid=CS-ZC-FT-305627 May 30, 2018 - Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.

Pages: 123456...23

Page 1>

Related Companies

Name Exchange Price Mkt Cap
PCRX Pacira Pharmaceuticals, Inc. NASDAQ $46.25 $1.89B
PTLA Portola Pharmaceuticals, Inc. NASDAQ $28.42 $1.88B
PBH Prestige Consumer Healthcare Inc. NYSE $38.5 $1.99B
ALLK Allakos Inc. NASDAQ $43.99 $1.85B
ARNA Arena Pharmaceuticals, Inc. NASDAQ $41.59 $2.05B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for TESARO